Phase III Readouts Will Broaden Pulmonary And Regenerative Markets

Published
22 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$379.32
17.7% undervalued intrinsic discount
14 Aug
US$312.06
Loading
1Y
-3.4%
7D
4.2%

Author's Valuation

US$379.3

17.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 3.12%

Shared on30 Apr 25
Fair value Decreased 1.71%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 1.33%

AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to 0.0%.

Shared on16 Apr 25
Fair value Increased 0.69%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 6.34%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 3.62%

Shared on26 Mar 25
Fair value Decreased 0.27%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 0.75%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 3.43%

AnalystConsensusTarget has decreased revenue growth from 9.4% to 7.2%.